Literature DB >> 9028337

Protoporphyria induced by the orally active iron chelator 1,2-diethyl-3-hydroxypyridin-4-one in C57BL/10ScSn mice.

A G Smith1, B Clothier, J E Francis, A H Gibbs, F De Matteis, R C Hider.   

Abstract

Administration in the drinking water of the orally-active iron chelator 1,2-diethyl-3-hydroxypyridin-4-one (CP94) to C57BL/10ScSn mice caused the development of hepatic protoporphyria. This was detected after 1 week and continued as long as the chelator was given (15 weeks). The more hydrophilic 1,2-dimethyl- and 1-hydroxyethyl,2-ethyl-analogues (CP20 and CP102) were also tested, but they were both inactive in inducing accumulation of protoporphyrin in the liver. Restriction of in vivo iron supply for ferrochelatase seemed a likely mode of action, but an approximately 30% decrease in activity of this enzyme was also observed when measured in vitro. Extracts of livers from mice given CP20, CP94, and CP102 showed no potential to inhibit mouse ferrochelatase, in contrast to the findings with an extract from mice treated with the known porphyrogenic chemical 4-ethyl-3, 5-diethoxycarbonyl-2,6-dimethyl-1,4-dihydropyridine, indicating that ferrochelatase inhibition did not occur by the formation of an N-ethyl-protoporphyrin derived from metabolism by cytochrome P450, CP20, CP94, CP102, and CP117 (the pivoyl ester of CP102) all caused significant depression of the levels of ferritin-iron and total nonheme iron, but only CP94 caused the significant accumulation of protoporphyrin. Protoporphyria did not occur with iron overloaded C57BL/10ScSn mice or in SWR mice that had elevated basal iron status. Although the protoporphyrin had only a small effect on the total levels of the hemoprotein cytochrome P450 in C57BL/10ScSn mice, the activity of the CYP2B isoforms of cytochrome P450 was actually induced in both strains. The results show that CP94 could cause protoporphyria in individuals of low iron status, perhaps through specifically targeting particular iron pools available to ferrochelatase and by concomitantly stimulating heme synthesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028337

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Feline porphyria associated with anemia, severe hepatic disease, and renal calculi.

Authors:  Jonathan J Schnier; Paul Hanna
Journal:  Can Vet J       Date:  2010-10       Impact factor: 1.008

2.  Complex response to physiological and drug-induced hepatic heme demand in monoallelic ALAS1 mice.

Authors:  Viktoria Vagany; Susan Robinson; Tatyana Chernova; Andrew G Smith
Journal:  Mol Genet Metab Rep       Date:  2021-11-12

3.  Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.

Authors:  Andrew Pye; Sandra Campbell; Alison Curnow
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-01       Impact factor: 4.553

4.  Fine-mapping and genetic analysis of the loci affecting hepatic iron overload in mice.

Authors:  Xin Guo; Zhuzhen Zhang; Fan Zhang; Yunlong Tao; Peng An; Qian Wu; Chia-Yu Wang; Mitchell D Knutson; Fudi Wang
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

5.  An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.

Authors:  Lizette Anayo; Anette Magnussen; Alexis Perry; Mark Wood; Alison Curnow
Journal:  Lasers Surg Med       Date:  2018-03-31       Impact factor: 4.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.